Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: Secondary analysis of data from a phase 3 randomised controlled trial

The Lancet Infectious Diseases

Volumn 15, Issue 12, 2015, Pages 1450-1458

  White, Michael T ^a   Verity, Robert ^a   Griffin, Jamie T ^a   Asante, Kwaku Poku ^b   Owusu Agyei, Seth ^b,c   Greenwood, Brian ^c   Drakeley, Chris ^c   Gesase, Samwel ^d   Lusingu, John ^d,e   Ansong, Daniel ^f   Adjei, Samuel ^g   Agbenyega, Tsiri ^f   Ogutu, Bernhards ^h   Otieno, Lucas ^h   Otieno, Walter ^h   Agnandji, Selidji T ^i,j,k   Lell, Bertrand ^i,j,k   Kremsner, Peter ^i,j,k   Hoffman, Irving ^l   Martinson, Francis ^m   Kamthunzu, Portia ^m   Tinto, Halidou ⁿ   Valea, Innocent ⁿ   Sorgho, Hermann ⁿ   Oneko, Martina ^o   Otieno, Kephas ^o   Hamel, Mary J ^p   Salim, Nahya ^q   Mtoro, Ali ^q   Abdulla, Salim ^q   Aide, Pedro ^r   Sacarlal, Jahit ^r,s   Aponte, John J ^r,t   Njuguna, Patricia ^u   Marsh, Kevin ^v,w   Bejon, Philip ^u,v   Riley, Eleanor M ^c   Ghani, Azra C ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KINTAMPO HEALTH RESEARCH CENTRE   (Ghana)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Tanzania National Institute for Medical Research   (Tanzania)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^g Agogo Presbyterian Hospital   (Ghana)

^h KEMRI Walter Reed Project   (Kenya)

ⁱ Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k German Center for Infection Research   (Germany)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

ⁿ Centre National de la Recherche Scientifique et Technologique   (Burkina Faso)

^o KEMRI CDC Public Health and Research Collaboration   (Kenya)

^p CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^q IFAKARA HEALTH INSTITUTE   (Tanzania)

^r Ministérioda Saúde   (Mozambique)

^s EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^t CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^u KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^v UNIVERSITY OF OXFORD   (United Kingdom)

^w AFRICAN ACADEMY OF SCIENCES   (Kenya)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PARASITE ANTIBODY; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; SUBUNIT VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; PARASITE TRANSMISSION; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SEROLOGY; VACCINATION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GHANA; IMMUNOLOGY; INCIDENCE; KENYA; MALARIA, FALCIPARUM; MALE; MULTICENTER STUDY; PARASITOLOGY; PLASMODIUM FALCIPARUM; SECONDARY IMMUNIZATION; TANZANIA; TREATMENT OUTCOME;

ANTIBODIES, PROTOZOAN; FEMALE; GHANA; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; KENYA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TANZANIA; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT;

EID: 84951567221     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00239-X     Document Type: Article

References (31)

1. World Malaria Report 2014, WHO, World Health Organization, Geneva.
2. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014, 11:e1001685. RTS,S Clinical Trials Partnership.
3. Final results from a phase 3, individually randomised, controlled trial of the RTS,S/AS01 malaria vaccine in African infants and children, including an evaluation of the efficacy of a booster dose. Lancet 2015, 386:31-45. RTS,S Clinical Trials Partnership.
4. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
5. Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011, 11:102-109.
6. White MT, Bejon P, Olotu A, et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med 2014, 12:117.
7. Bejon P, White MT, Olotu A, et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013, 13:319-327.
8. Sauerwein RW, Roestenberg M, Moorthy VS Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11:57-64.
9. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366:2012-2018.
10. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120.
11. Durham LK, Longini IM, Halloran ME, Clemens JD, Nizam A, Rao M Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 1998, 147:948-959.
12. Lievens M, Aponte JJ, Williamson J, et al. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children. Malar J 2011, 10:222.
13. Swysen C, Vekemans J, Bruls M, et al. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 2011, 10:223.
14. Griffin JT, Ferguson NM, Ghani AC Estimates of the changing age-burden of P. falciparum malaria disease in sub-Saharan Africa. Nat Commun 2014, 5:3136.
15. Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou Y-H Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine 2008, 26:6064-6067.
16. Moorthy V, Ballou WR Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J 2009, 8:312.
17. Hill AVS Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 2006, 6:21-32.
18. White MT, Griffin JT, Drakeley CJ, Ghani AC Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J 2010, 9:82.
19. Bojang KA, Milligan PJM, Pinder M, et al. Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358:1927-1934.
20. Prentice RL Surrogate endpoints in clinical-trials-definition and operational criteria. Stat Med 1989, 8:431-440.
21. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007, 196:1304-1312.
22. Seder RA, Chang L-J, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
23. Bijker EM, Bastiaens GJH, Teirlinck AC, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 2013, 110:7862-7867.
24. White MT, Griffin JT, Riley EM, et al. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proc Biol Sci B 2011, 278:1298-1305.
25. Plotkin SA Complex correlates of protection after vaccination. Clin Infect Dis 2013, 56:1458-1465.
26. Olotu A, Moris PJ, Mwacharo J, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P. falciparum clinical malaria. PLoS One 2011, 6:e25786.
27. White MT, Bejon P, Olotu A, et al. The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 2013, 8:e61395.
28. White MT, Griffin JT, Akpogheneta O, et al. Dynamics of the antibody response to Plasmodium falciparum infection in African children. J Infect Dis 2014, 210:1115-1122.
29. Amanna IJ, Carlson NE, Slifka MK Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
30. Amanna IJ, Slifka MK Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138.
31. White M, Griffin JT, Ghani AC The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum. Malar J 2013, 12:278.